Evidence map›Paper›PMID 40402298›Full record

Trial reportJournal of neurology2025

Patients' experience with and perspectives on long-term use of continuous subcutaneous infusion of foslevodopa/foscarbidopa in Parkinson's disease.

Michael Soileau, Rajeev Kumar, Ashwini Parab, Triza Brion, Kailee White, Connie H Yan, Megha B Shah, Pavnit Kukreja, Maurizio F Facheris, Anand Shewale and 1 more

Registry-linked trialAbstract readClinical Trial, Phase III
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04750226 (An Open-Label Extension of Studies M15-736 and M20-339 to Evaluate the Safety and Tolerability of 24-Hour Daily Exposure of ABBV-951 in Subjects With Advanced Parkinson's Disease), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04750226 phase3completednot on this map

An Open-Label Extension of Studies M15-736 and M20-339 to Evaluate the Safety and Tolerability of 24-Hour Daily Exposure of ABBV-951 in Subjects With Advanced Parkinson's Disease

TypeinterventionalSponsorAbbVieRan2021 to 2026Enrolled118ConditionsParkinson's Disease (PD)ArmsABBV-951
3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Michael SoileauTexas Movement Disorder Specialists, Georgetown, TX, 78628, USA. msoileau@txmds.net.ORCID http://orcid.org/0000-0002-3944-1327
Rajeev KumarRocky Mountain Movement Disorders Center, Englewood, CO, USA.
Ashwini ParabAbbVie, North Chicago, IL, USA.
Triza BrionICON Plc, Oakland, CA, USA.
Kailee WhiteLumanity, Patient-Centered Outcomes, Boston, MA, USA.
Connie H YanAbbVie, North Chicago, IL, USA.
Megha B ShahAbbVie, North Chicago, IL, USA.
Pavnit KukrejaAbbVie, North Chicago, IL, USA.
Maurizio F FacherisVanqua Bio, Chicago, IL, USA.
Anand ShewaleAbbVie, North Chicago, IL, USA.
Jason AldredSelkirk Neurology and Inland Northwest Research, Spokane, WA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesWe aimed to assess ease of use, convenience, self-efficacy, and satisfaction with long-term use of foslevodopa/foscarbidopa (LDp/CDp), a 24-h continuous subcutaneous infusion therapy delivered via an external portable pump for managing motor fluctuations in people with Parkinson's disease (PwP).

methodsPwP using LDp/CDp for ≥ 6 months and enrolled in an open-label study participated in semi-structured interviews, which were qualitatively analyzed using a content and thematic approach.

resultsNineteen adults, with an average (standard deviation) age of 63.6 (10.8) years, disease duration of 9.2 (3.4) years, and duration of LDp/CDp use of 15.4 (3.4) months, were interviewed. Most found LDp/CDp to be user-friendly (89.5%) and reliable (100%), and developed strategies to integrate the pump into their daily lives. The pump was commonly worn crossbody or around the waist, with minimal impact on sleep, though participants emphasized being mindful of the infusion set tubing to prevent tangling. Participants established routines using reminders, alarms, or schedules, and 84.2% prepared the pump in ≤ 20 min. Most (81.3%) were confident using LDp/CDp independently and 92.3% were satisfied with LDp/CDp, citing improved, consistent symptom control that allowed more freedom to participate in daily and social activities. Participants suggested improvements for the pump, including making it smaller and lighter.

conclusionPwP expressed high satisfaction and willingness to continue using LDp/CDp. PwP and their care partners developed innovative strategies to integrate the pump into daily routines, and the perceived symptom improvement drove successful persistence on this well-tolerated treatment.

trial registrationNCT04750226; started February 18, 2021.

Indexed as

Antiparkinson AgentsCarbidopaLevodopaParkinson DiseasePatient SatisfactionAgedDrug CombinationsFemaleHumansInfusions, SubcutaneousMaleMiddle AgedAntiparkinson AgentsCarbidopacarbidopa, levodopa drug combinationDrug CombinationsLevodopaDevice aided therapyFoslevodopa/foscarbidopaLevodopa/carbidopaParkinson’s diseaseSubcutaneous infusionSubcutaneous injection

Identifiers

PMID40402298
PMCPMC12098408

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.